• 1
    Ensrud KE, Blackwell T, Mangione CM et al. Central nervous system active medications and risk for fractures in older women. Arch Intern Med 2003; 163: 94957.
  • 2
    O'Neill TW, Varlow J, Reeve J et al. Fall frequency and incidence of distal forearm fracture in the UK. J Epidemiol Community Health 1995; 49: 5978.
  • 3
    Parkkari J, Kannus P, Palvanen M et al. Majority of hip fractures occur as a result of a fall and impact on the greater trochanter of the femur: a prospective controlled hip fracture study with 206 consecutive patients. Calcif Tissue Int 1999; 65: 1837.
  • 4
    Ensrud KE, Blackwell TL, Mangione CM et al. Central nervous system-active medications and risk for falls in older women. J Am Geriatr Soc 2002; 50: 162937.
  • 5
    Lovell SJ, Taira T, Rodriguez E, Wackett A, Gulla J, Singer AJ. Comparison of valdecoxib and an oxycodone-acetaminophen combination for acute musculoskeletal pain in the emergency department: a randomized controlled trial. Acad Emerg Med 2004; 11: 127882.
  • 6
    Frank L. Epidemiology. When an entire country is a cohort. Science 2000; 287: 23989.
  • 7
    Andersen TF, Madsen M, Jørgensen J, Mellemkjær L, Olsen JH. The Danish National Hospital Register. Dan Med Bull 1999; 46: 2638.
  • 8
    Vestergaard P, Mosekilde L. Fracture risk in patients with celiac disease, Crohn's disease, and ulcerative colitis: a nation-wide follow-up study in 16,416 patients in Denmark. Am J Epidemiol 2002; 156: 110.
  • 9
    Phillips S, Fox N, Jacobs J, Wright WE. The direct medical costs of osteoporosis for American women aged 45 and older, 1986. Bone 1988; 9: 2719.
  • 10
    Wacholder S, McLaughlin JK, Silverman DT, Mandel JS. Selection of controls in case-control studies. I. Principles. Am J Epidemiol 1992; 135: 101928.
  • 11
    Capella D. Descriptive tools and analysis. In: DukesMNG, ed. Drug Utilization Studies: Methods and Uses. Copenhagen: WHO Regional Publications, European Series No. 45, 1993; 5578.
  • 12
    Nielsen GL, Sørensen HT, Zhou W, Steffensen FH, Olsen J. The pharmaco-epidemiologic prescription database of North Jutland. Int J Risk Saf Med 1997; 10: 2035.
  • 13
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 1987; 40: 37383.
  • 14
    De Groot V, Beckerman H, Lankhorst GJ, Bouter LM. How to measure comorbidity. a critical review of available methods. J Clin Epidemiol 2003; 56: 2219.
  • 15
    Munk-Jørgensen P, Mortensen PB. The Danish Psychiatric Central Register. Dan Med Bull 1997; 44: 824.
  • 16
    Miettinen OS. Theoretical Epidemiology: Principles of Occurrence Research in Medicine, 1 edn. New York: Wiley & Sons, 1985.
  • 17
    Vestergaard P, Mollerup CL, Frøkjær VG, Christiansen P, Blichert-Toft M, Mosekilde L. Cohort study of risk of fracture before and after surgery for primary hyperparathyroidism. BMJ 2000; 321: 598602.
  • 18
    Laitinen K, Valimaki M. Alcohol and bone. Calcif Tissue Int 1991; 49(Suppl.): S703.
  • 19
    Black DM, Cummings SR, Kerpf DB et al. Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996; 348: 153541.
  • 20
    Clausen TG. International opioid consumption. Acta Anaesthesiol Scand 1997; 41(1 Pt 2): 1625.
  • 21
    Hoidrup S, Grønbæk M, Gottschau A, Lauritzen JB, Schroll M. Alcohol intake, beverage preference, and risk of hip fracture in men and women. Am J Epidemiol 1999; 149: 9931001.
  • 22
    Ray NF, Chan JK, Thamer M, Melton LJ. Medical expenditures for the treatment of osteoporotic fractures in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997; 12: 2435.